Health ❯ Healthcare ❯ Clinical Trials

Drug Efficacy

Patient Outcomes Side Effects Weight Loss Drugs Comparative Studies Weight Loss Results Lenacapavir Combination Therapy Semaglutide Lecanemab Trials GLP-1 Receptor Agonists Alzheimer's Treatments Leqembi Semaglutide Trials Weight Loss Trials Weight Loss Medications Cognitive Decline Lecanemab Novo Nordisk Wegovy Baxdrostat Wegovy Trials Weight Loss Outcomes Ivermectin Mounjaro Trials Capivasertib Trials Gonorrhea Treatment Orforglipron Study Results Obexelimab Palivizumab Zenith Trial Ubrogepant Weight-loss Injections Statin Therapy Obicetrapib Sub-Saharan Africa Cognitive Impairment Pain Relief Mechanisms Lynkuet Amycretin Trials EMPACT-MI Trial Early Stage Trials Alyftrek Results Ivonescimab Placebo-Controlled Trials Weight Regain Studies Cardiovascular Protection Teplizumab Trials Mifepristone Complications Eli Lilly Enfortumab Vedotin and Pembrolizumab Elamipretide Semaglutide and Tirzepatide Vasomotor Symptoms Taletrectinib Monoclonal Antibodies Weight Loss Injections Hidradenitis Suppurativa International Studies Obefazimod Psoriasis Treatments Lenacapavir Studies Tumor Growth Mounjaro Results Nuzolvence and Blujepa Zanubrutinib and Venetoclax Orforglipron Study Enlicitide Trial Influenza Prevention Biosimilar Efficacy Weight Loss FDA Approval Process Orforglipron Addyi Metabolic Dysfunction-Associated Steatohepatitis Placebo Effect Asthma Exacerbations Weight Loss Studies Wegovy Study Results Pre-exposure Prophylaxis (PrEP) Lecanemab and Donanemab Tirzepatide Study Long-term Effects SGLT-2 Inhibitors Vutrisiran COVID-19 Studies Phase Three Trials Pembrolizumab Kisunla Nirsevimab Trials Donanemab Real-World Evidence Amycretin Amycretin Studies Obesity Treatments Patient Safety Zepbound Semaglutide Study Alzheimer's Treatment

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

The company plans regulatory filings after the 52-week study delivered positive efficacy with favorable safety.

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

Abivax’s Obefazimod Meets Phase 3 Week-8 Remission Goals in Ulcerative Colitis

Metsera’s Obesity Drug Posts 14% Placebo-Adjusted Weight Loss, Bolstering Pfizer Buyout Case

Baxdrostat Lowers Blood Pressure in Hard-to-Treat Patients in Phase III Trial

Paclitaxel Reengineered Into Self-Assembling Nanovesicle Shows Strong Preclinical Gains

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Statins Linked to 39% Drop in 28-Day Mortality for Sepsis Patients

Sotatercept cuts risk of death and hospitalization by 76% in advanced pulmonary arterial hypertension

Duke's SBI-810 Shows Promise as Non-Opioid Painkiller in Preclinical Studies